Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Speaking Engagement
In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

WilmerHale Partner Mark Ford will be a featured speaker on this panel.

Read More About the Event

Speakers

You May Be Interested In

Health Care Privacy 101 and Beyond

September 1, 2026
Speaking Engagement

Data Subject Rights: What Happens After the Request Comes In

September 8, 2026
Speaking Engagement

2026 POWER Act Webinar for District Courts in the Ninth Circuit

September 15, 2026
Speaking Engagement
View all Events

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel